Mayinglong

Mayinglong is a Chinese pharmaceutical brand associated with Mayinglong Pharmaceutical Group Co., Ltd., a Wuhan-based drug manufacturer. The brand is especially recognized in China for hemorrhoid-care products, including its flagship hemorrhoid ointment, and for its broader portfolio of traditional Chinese medicine and over-the-counter pharmaceutical products. The company’s public-facing identity combines pharmaceutical manufacturing with the Mayinglong consumer brand. Its best-known products address anorectal conditions and related discomfort, giving the brand a strong specialist association rather than the broad, general-purpose positioning of a mass consumer-health company. Mayinglong’s hemorrhoid products are sold primarily through China’s pharmaceutical retail and healthcare distribution channels, with the group also presenting an international business presence on its corporate website. Mayinglong’s commercial significance rests on the familiarity of its name in China’s hemorrhoid-treatment category. The brand has become closely linked with topical and other non-surgical treatments for hemorrhoid symptoms, while the corporate group maintains activity in traditional Chinese medicine and other pharmaceutical areas. Product availability, regulatory classification, formulations, and market claims can vary by product and jurisdiction. The available reference material confirms the company’s official website, Wuhan base, pharmaceutical identity, and Shanghai Stock Exchange listing, but does not establish a reliable founding date, founder, executive roster, detailed international market list, or a complete chronology of product launches and corporate events. Those fields are therefore left unfilled rather than inferred.

Mayinglong is the principal consumer-facing pharmaceutical brand associated with Mayinglong Pharmaceutical Group Co., Ltd. The company is headquartered in Wuhan, China, and its official corporate website identifies the group as a listed pharmaceutical enterprise. The brand is most strongly associated with hemorrhoid care, particularly its hemorrhoid ointment, while the group also operates across traditional Chinese medicine and other over-the-counter pharmaceutical categories. Rather than being positioned solely as a single-product trademark, Mayinglong functions as a corporate pharmaceutical brand. Its name is used across a range of products and communications, with hemorrhoid treatment providing the clearest point of recognition in the Chinese market. This specialist association has helped distinguish Mayinglong from broader healthcare companies whose portfolios span many unrelated therapeutic categories. The available source material does not provide a sufficiently documented founding chronology, named founder, product-by-product launch history, or detailed account of the company’s international expansion. It also does not establish a verified list of current or former executives, major campaigns, scandals, acquisitions, or pricing decisions. Accordingly, this dossier records the confirmed corporate and category information while avoiding unsupported historical claims.

• 2024

  The China Association of Chinese Medicine releases the expert consensus on clinical application of Longzhu Ointment.

• 2022

  Mayinglong launches a plan to co-build 100 key anorectal specialty departments nationwide.

• 2011

  The inherited eye-medicine making technique is named a national intangible cultural heritage.

• 2009

  Mayinglong Babao eye cream, the company's first functional cosmetic, is launched.

• 1995

  Shareholding reform; the Mayinglong trade name is fully restored after 30 years.

• 1922

  The Wuhan shop survives looting during warlord Wang Zhanyuan's troop mutiny.

• 1919

  Ma Qishan moves south and opens a branch in Wuchang, Wuhan.

• 1582

  Ma Jintang creates 'Dingzhou eye medicine' in Dingzhou, Hebei, during the Ming Wanli era.

• Ma Yinglong commercializes the formula as 'Mayinglong Dingzhou eye medicine' and opens a shop in Dingzhou.

• During the Daoguang reign, Ma Wanxing moves the business to Beijing.

A Chinese pharmaceutical and consumer-health brand with specialist authority in hemorrhoid care, supported by a broader traditional Chinese medicine and over-the-counter medicine portfolio.

• Over-the-counter hemorrhoid treatment

  Mayinglong Hemorrhoid Ointment

  The brand’s best-known offering is a topical hemorrhoid ointment sold under the Mayinglong name. It is associated with the company’s specialist position in hemorrhoid care and with its wider traditional Chinese medicine and consumer-health portfolio. Exact formulation, indications, regulatory status, packaging, and availability may differ across markets and product versions.

• Over-the-counter hemorrhoid treatment

  Mayinglong Hemorrhoid Suppositories

  Hemorrhoid suppositories are part of the type of anorectal-care product range associated with Mayinglong. They extend the brand beyond topical ointment into another route of administration for hemorrhoid-related treatment. Product composition, classification, approved claims, and market availability should be verified against the relevant local regulatory listing.

• Traditional Chinese medicine

  Mayinglong Traditional Chinese Medicine Products

  Mayinglong’s corporate pharmaceutical portfolio includes traditional Chinese medicine products beyond its signature hemorrhoid-care line. The available reference material does not provide a complete or authoritative product catalogue, so this entry describes the portfolio at category level rather than assigning specific therapeutic indications or product names not confirmed by the source.

• 2025

  Mayinglong Pharmacy embroiled in 'recirculated drugs' and medical-insurance violations; multiple stores' insurance agreements terminated

  In March 2025, Mayinglong Pharmacy became embroiled in a "recirculated drugs" controversy, and about 40 of its medical-insurance designated pharmacies were investigated; among them, a pharmacy in Huiji, Zhengzhou, had 1.44588 million yuan of medical-insurance funds recovered for settling drug claims with forged prescriptions and had its medical-insurance service agreement terminated. In January 2026, another store had 7,256.6 yuan recovered for empty swiping of medical-insurance cards and had its medical-insurance agreement terminated. Media said strong performance could not conceal the compliance controversy.

  Source

• 2020

  Erythromycin ointment fails drug spot check, cited in notice

  In January 2020, erythromycin ointment produced by Mayinglong failed content determination in a drug spot check and was cited by drug regulators; reports said its subsidiary had previously been penalized multiple times for violations. The relevant batches were controlled and rectified.

  Source

Read more

• 2020.11.26

  Mayinglong and five pharmacy chains run sanitation worker care campaign[8]马应龙携手五大连锁开展关爱环卫工人公益活动hy.stock.cnfol.com

  Mayinglong Pharmaceutical and five pharmacy chains held a public welfare event across Shaanxi, Sichuan, Hubei, Shanxi and Gansu, providing sanitation workers with health checks, health education, medical consultations and supplies.

Read more

1. 1Mayinglong Pharmaceutical Group official websitemayinglong.cn
2. 2品牌故事-马应龙集团mayinglong.cn
3. 3品牌资讯-马应龙集团mayinglong.cn
4. 4公司简介-马应龙集团mayinglong.cn
5. 5Mayinglong Pharmacy embroiled in 'recirculated drugs' and medical-insurance violations; multiple stores' insurance agreements terminatednews.qq.com
6. 6Mayinglong Pharmacy embroiled in 'recirculated drugs' and medical-insurance violations; multiple stores' insurance agreements terminatedeeo.com.cn
7. 7Erythromycin ointment fails drug spot check, cited in noticefinance.china.com.cn
8. 8马应龙携手五大连锁开展关爱环卫工人公益活动hy.stock.cnfol.com